Optimized Conformal Total Body Irradiation Among Recipients of TCRαβ/CD19-Depleted Grafts in Pediatric Patients With Hematologic Malignancies: Single-Center Experience

Daria Kobyzeva1†, Larisa Shelikhova2†, Anna Loginova1†, Francheska Kanestri1†, Diana Tovmasyan1†, Michael Maschan2†, Rimma Khismatullina2, Mariya Ilushina2, Dina Baidildina3, Natalya Myakova4 and Alexey Nechesnyuk1†

1 Department of Radiation Oncology, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia, 2 Department of Hematopoietic Cell Transplantation, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia, 3 Department of Pediatric Hematology and Oncology, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia, 4 Department of Oncology, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Total body irradiation (TBI) in combination with chemotherapy is widely used as a conditioning regimen in pediatric and adult hematopoietic stem cell transplantation (HSCT). The combination of TBI with chemotherapy has demonstrated superior survival outcomes in patients with acute lymphoblastic and myeloid leukemia when compared with conditioning regimens based only on chemotherapy. The clinical application of intensity-modulated radiation therapy (IMRT)-based methods (volumetric modulated arc therapy (VMAT) and TomoTherapy) seems to be promising and has been actively used worldwide. The optimized conformal total body irradiation (OC-TBI) method described in this study provides selected dose reduction for organs at risk with respect to the most significant toxicity (lungs, kidneys, lenses). This study included 220 pediatric patients who received OC-TBI with subsequent chemotherapy and allogenic HSCT with TCRαβ/CD19 depletion. A group of 151 patients received OC-TBI using TomoTherapy, and 40 patients received OC-TBI using the Elekta Synergy™ linac with an Agility-MLC (Elekta, Crawley, UK) using volumetric modulated arc therapy (VMAT). Twenty-nine patients received OC-TBI with supplemental simultaneous boost to bone marrow—(SIB to BM) up to 15 Gy; 28 patients (pts)—TomoTherapy; one patient—VMAT. The follow-up duration ranged from 0.3 to 6.4 years (median follow-up, 2.8 years). Overall survival (OS) for all the patients was...
INTRODUCTION

Total body irradiation (TBI) in combination with chemotherapy is widely used worldwide as a conditioning regimen prior to transplanting hematopoietic stem cells in patients with malignant hematological diseases.

The main benefits of TBI include tumor cell elimination and general immunosuppressive effects. The combination of TBI with chemotherapy has demonstrated superior survival results in patients with acute lymphoblastic and myeloid leukemia when compared with conditioning regimens, including chemotherapy alone (1–7). However, TBI-based regimens show significant disadvantages for intermediate and long-term toxicity, especially pulmonary toxicity (up to 33% incidence of grade 3+) (8, 9). The incidence of pneumonitis after TBI-conditioning regimens varies, covering a range of 10.3%–45%, and it depends on many factors, such as patient characteristics and treatment technique (10–12). For many years, conventional techniques using low-dose rates (5–15 cGy/min) and lung shielding have historically been a method of choice for TBI treatment (13–16). The irradiation of healthy organs and tissues with high radiosensitivity, such as the lungs and kidneys, may occasionally bring about lethal side effects (8, 11, 17). The disadvantage of the conventional TBI treatment technique is the lack of sparing organs at risk (OARs), with the exception of the lungs. In addition, there is no capability to measure the dose in a small voxel volume and to create dose/volume histograms (DVHs) for the planning target volume (PTV) and OARs to correlate toxicities with received radiation doses.

The clinical application of modern radiotherapy methods, such as intensity-modulated radiation therapy (IMRT), as well as the feasibility of irradiation of extended targets with helical TomoTherapy, have been investigated for TBI and total bone marrow and lymphoid irradiation (TMLI) in adult patients (18–21). However, the number of reports on the application of these methods for the treatment of pediatric patients remains limited (22–25).

In our center, pediatric patients with hematologic malignancies receive TCR-alpha/beta-depleted grafts to minimize the incidence of GVHD and to achieve fast immune reconstitution after HSCT (26–28).

Our goal was to develop and implement the optimized conformal total body irradiation (OC-TBI) method in pediatric practice as a part of the patient conditioning protocol prior to allogeneic bone marrow transplantation (29, 30). The OC-TBI method described in this study provides reproducible dose reduction for OARs that are prone to significant radiotoxicity (lungs, kidneys, lenses).

The main objective of OC-TBI is to irradiate the PTV with maximum homogeneity with simultaneous dose reduction to the critical organs with planning and treatment optimization based on the age of pediatric patients.

We present initial experience and results of implementing the new TomoTherapy- and VMAT-based OC-TBI method in pediatric practice and the toxicity and survival rates in TCRαβ/CD19-depleted graft recipients.

The IMRT-based OC-TBI method provides the opportunity to deliver additional doses to sanctuary sites (i.e., bone marrow, extramedullary sites) to improve radiation treatment effectiveness for advanced patients (30, 31).

We also report outcomes for patients with refractory leukemia who received local dose escalation (boost) to bone marrow.

MATERIALS AND METHODS

Patient Characteristics

Two hundred and twenty (220) patients underwent optimized conformal IMRT-based total body irradiation (OC-TBI) in a myeloablative conditioning regimen at the Radiotherapy Department of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology in Moscow, Russia between July 2012 and September 2020. Radiation therapy was followed by chemotherapy and allogenic HSCT with TCRαβ/CD19 depletion. The majority of the patients had ALL (n = 165). All patients were included in the respective high-risk groups. Detailed patient characteristics are presented in Table 1. All the data were retrieved from the patients’ medical records.

Immediately after OC-TBI treatment, the patients received chemotherapy according to the different schedules. Conditioning...
regimens, donor type, and graft composition details are provided in Table 1.

Twenty-nine patients (13%) (19 with active disease prior to HSCT) received radiation treatment with simultaneous integrated boost to bone marrow (SIB to BM) with doses up to 15 Gy followed by chemotherapy in accordance with an individual schedule based on unfavorable performance status and/or the etiology of the main disease.

The study was approved by the local ethics committee of the Dmytriy Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology, in accordance with the Helsinki Declaration, and patients and/or their legal guardians provided informed consent to participate in the study.

Radiation Therapy Preparation
CT Simulation
Our Radiation Therapy Department is equipped with one TomoTherapy™, Accuray Inc. (Sunnyvale, CA, USA) and two Elekta Synergy™ treatment units with an Agility-MLC (Elekta) and one CT scanner—GE LightSpeed RT16.

Approximately 1 week prior to the treatment, all the patients underwent CT simulation using individualized fixation. The patients were immobilized in the supine position, laid in vacuum bags for body and extremity fixation, and used thermoplastic masks for head and neck fixation, as shown in Figure 1.

Following patient fixation, planning CT images were acquired using slice thicknesses of 5 mm. Patients taller than 115 cm were scanned twice. The first scan included the upper part of the body down to the knee joints, and the second scan included legs from the toes up to the upper third of the thigh. A fiducial marker was placed in the middle of the thigh to assist in determining the juncture between the two images.

Thirty-two patients (15%) of younger ages underwent both CT simulation and radiotherapy treatment under general anesthesia.

Dose Prescription
Monaco 5.11 (Elekta Inc.) MIM Maestro™ software was used to contour the target and OAR volumes.

The lungs, kidneys, and lenses were selected as critical organs based on reported literature data (4, 6, 8–11, 32–35).

The PTV included the patient’s whole body minus critical structures (OARs). The following structures were created: external body contour, PTV (consisting of body without skin with 3 mm inner margin), eyes, lenses, lungs, and kidneys.

### TABLE 1 | Patient and treatment characteristics.

| Patients | (n = 220) |
|----------|-----------|
| Sex      |           |
| Male     | 151 (69%) |
| Female   | 69 (31%)  |
| Median (range) age at TBI (year) | 10.2 (3.0–21.0) |
| Disease                          |
| ALL                              |
| T-cell ALL                       | 63 (38% of ALL) |
| B-cell ALL                       | 102 (62% of ALL) |
| AML                              | 25 (11%) |
| Other (NHL, biphenotypic/bilineal leukemia, JMML) | 30 (14%) |
| Disease status at transplantation |
| ALL                              |
| CR 1                             | 44 (27%) |
| CR 2                             | 86 (52%) |
| ≥CR 3                            | 23 (14%) |
| Active disease                    | 12 (7%) |
| AML                              |
| CR 2/3                           | 5 (20%) |
| Active disease                    | 20 (80%) |
| Others                           |
| CR 1                             | 9 (30%) |
| CR 2/3                           | 14 (47%) |
| Active disease                    | 7 (23%) |
| Conditioning regimens            |
| OC-TBI 12 Gy                      | 220 (100%) |
| SIB to BM up to 15 Gy            | 29 (13%) |
| Fludarabine                       | 220 (100%) |
| Thiotepa                          | 164 (74%) |
| VP-16                             | 49 (22%) |
| Donor characteristics            |
| Type of donor                     |
| Haplo-                            | 192 (88%) |
| MSD                               | 14 (6%) |
| MUD                               | 14 (6%) |
| Cell dose infused, median (range) |
| CD34+ cells × 106/kg             | 9.21 (0.9–15.64) |
| αβ T cells × 103/kg              | 35.6 (4.3–377.2) |

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; JMML, juvenile myelomonocytic leukemia; CR, complete remission; OC-TBI, Optimized Conformal Total Body Irradiation; SIB to BM, simultaneous integrated boost to bone marrow; VP-16, etoposide; MSD, matched sibling donor; MUD, matched unrelated donor.
In cases when the patient’s body height exceeded 115 cm, the total body volume was divided into two planning target volumes—PTV_Body and PTV_Legs.

Additional contours were defined in support of treatment planning tasks. For dose control between eyes (small children have part of the brain located in this area), we additionally created the contour named the “forehead area” (Figure 2).

Ribs were contoured as an additional target volume within the PTV and with a set-prescribed Dmin for better control of steeply decreasing dose gradient in the area between lungs and PTV.

For the TomoTherapy patients, a virtual volume of 1 cm thickness was added to the PTV as an additional target (PTV+1 cm) and was used to account for the patient’s motion and breathing while providing the required dose to the skin (Figure 2). For the Elekta patients, we used the Monaco 5.11 (Elekta Inc., UK, Crawley) Auto-Flash option with a 1-cm margin.

For the patients who received SIB to BM, the contoured addition structure PTV_1500 included all skeletal bones. Treatment volume for skeletal bones in the case of SIB was created without additional margin.

The prescribed total dose for the PTV was 12 Gy delivered in single fractions of 2.0 Gy or 3.0 Gy. The prescribed total doses for OAR are given in Table 2.

We established targeted and acceptable values for all the structures with the objective of optimizing treatment planning and plan optimization procedures (Table 2).

TREATMENT PLANNING AND RESULTS

TomoTherapy 4.5 (Accuray Inc., Sunnyvale, CA, USA) and Monaco 5.11 (Elekta Inc.) planning systems were used for treatment planning. The received results with standard deviations after calculation of the treatment plans are presented in Table 3.

The separate treatment plan was created for PTV_Legs in feet-first rotate position with the 5-cm “juncture area” between “body” and “legs” treatment volumes for helical TomoTherapy patients.

Average dose volume histograms (DVHs) calculated for the 151 patients treated using TomoTherapy and 40 patients treated using VMAT are shown in Figure 3.

DOSIMETRIC QA

Quality assurance included absolute dosimetry for each treatment plan using dose measurements with an ionization chamber (ExtraDIN IND Chambers, A1SL), 8-channel electrometer (Tomo Elektrometer from Standart Imaging) and tissue equivalent phantom (Cheese Phantom). For the VMAT-based plans, individual checks included composite measurements of the two-dimensional dose distributions using an array of ionization chambers MatriXX (IBA Dosimetry).

RADIATION THERAPY TREATMENT CHARACTERISTICS

Fractionation

The treatment was carried out daily, with the fractions given twice a day with an interfraction interval of 5–6 h over 3 days (group 1). Since April 2020, we have revised the fractionation schedule and reduced the number of treatment sessions to minimize patient/staff contact due to COVID-19. The new treatment schedule included one treatment session per day.

FIGURE 2 | Anatomical differences in “forehead area” in the example of (A) 5- and (B) 14-year-old patients.
with a single dose of 3.0 Gy (group 2). Radiobiology modeling supposes that increased dose-per-fraction is associated with higher normal tissue toxicity (36). To determine the effect of this new fractionation schedule, we calculated DVHs using a linear quadratic model using different alpha/beta values with the help of MIM Maestro™ to assess the influence of increased single doses for organs at risk (lungs, kidneys). The increased single dose did not significantly affect the prescribed dose values for the lungs and kidneys (Figure 5).

**Treatment Procedure**

Positioning was verified prior to each treatment session using megavoltage (MV) CTs and cone-beam (CB)-CTs with subsequent corrections of the setup errors.

| Structure | Target value | Acceptable value |
|-----------|--------------|------------------|
| PTV       | Mean dose (12 Gy) ± 2% | Mean dose (12 Gy) ± 5% |
|           | D98% >11.4 Gy | D95% >11.4 Gy |
|           | D2% <13 Gy | D5% <13 Gy |
| Forehead  | D98% >11.4 Gy | D95% >11.4 Gy |
|           | D2% <13 Gy | D5% <13 Gy |
| Ribs      | D95% >10 Gy | D90% >10 Gy |
| Lungs     | D99% >6 Gy | D90% > 6Gy |
| Kidneys   | Dmean <8 Gy | Dmean < 8Gy |
| Lenses    | As low as achievable | As low as achievable |

**TABLE 2** | Dose prescriptions with “target” and “acceptable” values.

| Structure          | Target value  | Acceptable value  |
|--------------------|---------------|-------------------|
| PTV (Dmean)        | 12.05 ± 0.05  | 12.16 ± 0.12      |
| Lung_L (Dmean)     | 7.88 ± 0.12   | 7.62 ± 0.14       |
| Lung_R (Dmean)     | 7.84 ± 0.13   | 7.57 ± 0.14       |
| Lung_L (V8)        | 37.55 ± 3.82  | 38.81 ± 2.79      |
| Lung_R (V8)        | 36.52 ± 3.96  | 38.45 ± 2.66      |
| Kidney_L (Dmean)   | 7.44 ± 0.42   | 7.31 ± 0.35       |
| Kidney_R (Dmean)   | 7.49 ± 0.45   | 7.40 ± 0.29       |
| Ribs (Dmean)       | 11.21 ± 0.12  | 11.62 ± 0.21      |
| Lens_L             | 6.23 ± 0.55   | 6.13 ± 0.55       |
| Lens_R             | 6.10 ± 0.75   | 6.30 ± 0.51       |
| Forehead/Brain     | 12.01 ± 0.04  | 12.32 ± 0.09      |

**TABLE 3** | Treatment plan calculation results.

**FIGURE 3** | Dose volume histograms calculated in the TomoTherapy (A) and Monaco (B) Planning systems. Dotted lines show standard deviations.
The dose delivery time ranged from 16 to 50 min (average 30 min) and was dependent on the patient’s height. Dose delivery times were approximately the same for both the TomoTherapy and VMAT approaches. Total treatment time, including imaging and patient setup, was significantly different for the two methods, with up to 60 min for TomoTherapy and up to 90 min for VMAT.

Radiation therapy treatment was held with a 24-h intravenous infusion (Sodium Chloride 0.9% + sodium bicarbonate—125 ml/h). All the patients received preventive antivomiting prescription (antagonist of the 5-HT3 receptors: 4–8 mg, dexamethasone: 4–6 mg) once per day.

STATISTICAL ANALYSIS

Statistical analysis was performed using XLSTAT (Addinsoft, 2021) software.

Two hundred and twenty patients who received OC-TBI and underwent allogenic HSCT with TCRdβ/CD-19 depletion were included in the final analysis. Overall survival (OS) and event-free survival (EFS) were calculated using the Kaplan-Meier method. OS was defined as the probability of survival, regardless of disease status, from the time of TBI to the time of death or of the last follow-up (surviving patients were censored at the last follow-up, whereas only death from any cause was considered an event). The following events were considered for EFS: death from any cause, relapse and progression of the main disease (patients with advanced disease). We calculated transplant-related mortality (TRM) and relapse according to the competing risk model, where these two events were considered to be mutually competitive.

RADIATION-INDUCED TOXICITY EVALUATION AND RESULTS

We followed up patients for acute toxicity (nausea/vomiting/diarrhea, headache, veno-occlusive disease (VOD))—during radiation therapy and 30 days after SCT, subacute toxicity (IP)
—up to the 100th day after SCT and late toxicity in the lungs and kidneys—for at least 100 days after SCT in accordance with the RTOG/EORTC scale (37).

### Acute Toxicity: Results

Acute toxicity during radiation therapy was expressed in nausea and vomiting and headache, symptoms of parotitis and enteritis. We observed a correlation between the frequency of nausea/vomiting ($p = 0.02$) with the amount of a single radiation dose. We also noticed the larger number of patients with headache in 3 Gy/fraction group, and it seemed to be correlated with the amount of a single dose, but was not statistically significant ($p > 0.05$) (Table 4).

All patients were able to complete the planned radiation treatment program and received HSCT.

### Subacute Toxicity: Transplant-Related Toxicity and Death

Subacute toxicity among the patients who received OC-TBI ($n = 191$) was observed in 0.4% of the patients ($n = 1$) (interstitial pneumonia, 3–4 stage according to RTOG) at +81 days after TBI (Table 5). The patient died from respiratory failure. No radiation-induced kidney toxicity was observed among the patients.

Among the patients who received SIB to bone marrow up to 15 Gy (29 pts), we observed 3 (10%) cases of veno-occlusive disease (VOD), which appeared on days +14, +21, and +26. One patient developed transitory hepatic failure symptoms (Table 5). All these patients died from the disease relapse.

The cumulative incidence of TRM for the entire patient cohort was 10.7% (95% CI: 2.2–16).

Most of the TRM cases were induced by infection and subsequent sepsis with multiorgan failure ($n = 20$). One patient died because of the COVID-19 infection. The full list of infections and its localization is displayed in Table 6.

The incidence of TRM for the patients who received 1st HSCT was 8.7% (95% CI: 5.5–15), and it had significantly higher values for the patients with 2nd HSCT—18.7% (95% CI: 9.5–37.5) ($p = 0.03$) (see Figure 6). The cumulative incidence of early TRM (<100 days) was 5.0 (95% CI: 1.5–8.9), and that of late TRM (>100 days) was 5.7 (95% CI: 1.7–10.2).

The incidence of early TRM (<100 days) was significantly lower for the patients who were in complete remission (CR) before HSCT—3.9% (95% CI: 1.4–8.0) compared with active disease (AD) patients—9.0% (95% CI: 5.0–9.6) ($p < 0.0001$) (Figure 6).

### Survival Analysis

We retrospectively analyzed a cohort of 220 patients who received OC-TBI with subsequent allogeneic SCT with TCRβ/CD-19 depletion in our clinic during a period of time from July 2014 to September 2020.

The follow-up period was from 0.3 to 6.4 years (the median follow-up for the surviving patients—2.8 years).

The OS for all patients was 63% (95% CI: 56–70), and the EFS was 58% (95% CI: 51–65).

The OS in the patients with acute leukemia was 63% (95% CI: 43–71) in the ALL group and 52% (95% CI: 32–72) in the AML group ($p = 0.09$). The EFS for the patients with ALL was 57% (95% CI: 49–65), and the EFS for the patients with AML was 52% (95% CI: 32–72) ($p = 0.3$) (Table 7).

The OS and EFS for patients with other diseases (NHL, biphenotypic/bilinear leukemia, JMML, etc.) were more related to patients with ALL and AML, with an OS of 71% (95% CI: 54–88) and EFS of 70% (95% CI: 53–86). These results are attributed to the different disease characteristics in this group and are not significant (Table 7).

The OS and EFS values in the patients with CR before HSCT ($n = 181$) were 68% (95% CI: 60–76) and 63% (95% CI: 56–70), respectively.

The OS and EFS values for the patients with AD prior to HSCT were significantly lower: OS 36% (95% CI: 20–52) and EFS 36% (95% CI: 20–52) compared with the CR ($n = 181$) patients ($p < 0.0001$) (Figure 7). The patients who received treatment in the CR relapsed from the following sites: 36 patients had bone marrow relapse, one patient with ALL had isolated CNS relapse, 12 patients had combined relapses from bone marrow and extramedullary sites (Table 7).

#### TABLE 4 | Radiation-induced acute toxicity.

| Toxicity criteria (RTOG) | GROUP 1  | GROUP 2  | $p$-value |
|--------------------------|----------|----------|-----------|
|                          | 2 Gy x 6 fractions/twice daily | 3 Gy x 4 fractions |           |
| Number of pts            | 201      | 19       |           |
| Nausea and vomit         |          |          |           |
| • Grades 0–1             | 124 (62%)| 6 (32%)  | 0.020     |
| • Grades 2–3             | 77 (38%) | 13 (68%) |           |
| Headache                 |          |          |           |
| • Grades 0–1             | 114 (56%)| 12 (63%) | >0.05 (0.751)|
| • Grades 2–3             | 87 (44%) | 7 (39%)  |           |
| Parotitis                |          |          |           |
| • No clinical symptoms   | 109 (54%)| 9 (47%)  | >0.05 (0.755)|
| • Grade 1 clinical symptoms | 92 (46%) | 10 (53%) |           |
| Enterritis               |          |          |           |
| • No clinical symptoms   | 122 (61%)| 10 (53%) | >0.05 (0.733)|
| • Grade 1                | 64 (32%) | 7 (36%)  |           |
| • Grade 2                | 15 (7%)  | 2 (11%)  |           |
Active Disease Patients
A total of 39 patients had an active disease status prior to HSCT. Among those, 19 patients received conformal TBI with an additional dose escalation (SIB) to BM (Boost+), and 20 patients received 12 Gy conformal TBI (Boost−). We calculated and compared OS, EFS, and cumulative incidence of TRM and relapse in these two groups of patients.

We noticed the difference in the OS and the EFS among this group of patients: the OS and EFS for the Boost+ patients had the same value and was 47% (95% CI: 25–70), while among the Boost− patients OS, and EFS was 29% (95% CI: 8–49) and 27% (95% CI: 6–48) (p = 0.4) (Figure 8). The lower number of bone marrow recurrence/disease progression cases were registered in the Boost+ patients compared with the Boost− group—five (26%) versus nine (45%). The difference between bone marrow relapse rate in the described groups was not statistically significant (p-value = 0.342; Chi-square test). We did not observe CNS relapses in patients receiving SIB to BM.

Meanwhile, the cumulative incidence of TRM between the Boost− and Boost+ groups was equal, with a value of 15.8% (95% CI: 8–45).

**DISCUSSION**
The main aim of this study was to develop an optimized approach toward TBI planning in pediatric patients using IMRT and TomoTherapy-based conformal avoidance...
**FIGURE 6** | (A) The cumulative incidence of TRM <100-day curves, comparison of CR and AD patients. (B) The incidence of TRM in patients according to the number of HSCTs.

**TABLE 7** | The survival analysis results for the different patient groups.

| Disease status at HSCT | OS % (95%CI) | EFS % (95%CI) | Relapse site (number of pts) |
|------------------------|--------------|--------------|-----------------------------|
| CR 1/2/3 | 68 (60-76) | 63 (56-70) | BM – 36 |
| (182 pts) | | | BM + CNS – 6 |
| AD (39 pts) | | | BM + EM sites – 4 |
| AD SIB to BM + (19 pts) | 36 (20-52) | 36 (20-52) | BM + Testicles – 1 |
| AD SIB to BM – (20 pts) | 47 (25-70) | 47 (25-70) | BM + EM sites – 1 |
| | | | BM + uterus + ovaries – 1 |
| | | | BM + CNS – 1 |
| | | | BM + EM – 8 |

BM, bone marrow; CNS, central nervous system; EM, extramedullary site.
techniques and to evaluate the safety and potential efficacy of this treatment for patients with varying characteristics and disease features.

We did not observe any significant effect of OC-TBI with the described dose limits to the OAR organs at risk on transplant-related mortality. We observed that a single day of fractionation with a higher single dose increased acute radiation-induced toxicity (nausea/vomiting and headache). However, an additional investigation of other nonlethal toxicities for a larger number of patients and a longer follow-up period is required to elucidate disadvantages.

Considering the long-term survival period in a pediatric cohort with remission and a good response to received therapy, the development of radiation-induced late side effects (such as hormone dysfunction, hypogonadism, cognitive dysfunction, secondary malignancies) significantly influences

FIGURE 7 | The OS (A) and EFS (B) curves for the CR and AD patients.

FIGURE 8 | OS (A) and EFS (B) curves for AD patients who received SIB to BM.
the patient’s quality of life. In this manner, a preferred option for the TBI method would be to use it in combination with total bone marrow irradiation (TMI) and/or total lymphoid irradiation (TMLI). This approach would facilitate redistribution of the radiation dose within the patient’s body, leading to dose reduction to the OAR (such as gonads, thyroid, liver, etc.) with a simultaneous increase in the total dose to the bone marrow. Local dose escalation to sanctuary sites (such as bone marrow) with higher doses (up to 18–20 Gy) would likely lead to an increase in the survival rates for active disease patients (Figure 8), but it can also be complex in terms of higher toxicity incidence. We explored the initial feasibility of using IMRT and TomoTherapy techniques for planning and delivery of simultaneous additional dose escalation (SIB) to the bone marrow (BM) up to 15 Gy in patients with refractory leukemia. During the early follow-up, we observed a higher incidence of VOD in this group of patients \( n = 3 \) (10%). The EQD2-calculated liver dose for these patients and its comparison with OC-TBI are presented in Figure 9.

Taking into account the published data on the risk factors for VOD development (38–40), we assume that this issue can be resolved by further reducing the dose to the liver parenchyma. Even though TMLI provides a more conformally targeted radiotherapy for patients undergoing HCT, organ sparing could potentially increase the risk of extramedullary relapse and decrease the efficacy of radiation treatment.

We had early experience with seven patients who received a total marrow dose of 15 Gy plus a total lymphoid dose of 12 Gy irradiation using TMLI. At this point, it is too early to draw any conclusions regarding the effectiveness and survival rates for this treatment approach. Nevertheless, taking into account the VOD cases among the patients who received OC-TBI with SIB to bone marrow, we decided to replace this method with total marrow and lymphoid irradiation (with the additional dose reduction to the heart, liver, intestine, thyroid, ovaries, etc.). We saved a 12-Gy treatment dose to the most susceptible extramedullary sites for patients with pediatric leukemia (brain; forehead area for younger patients – Figure 2; testicles) and controlled the dose in these areas (D95 >11.4 Gy).

The concept of conformal total body irradiation (TBI) using IMRT VMAT and helical treatment delivery on a TomoTherapy accelerator provides the maximum control of the dose distribution in extended targets (PTV) with a simultaneous dose decrease in organs at risk. It leads to a reduced incidence of severe side effects after radiation therapy and high treatment effectiveness.

OC-TBI with precise dose prescription for organs at risk and image-guided treatment delivery allows us to estimate potential efficacy and radiation-induced toxicity in comparable groups of treated patients. The limited number of pediatric patients who receive OC-TBI requires multidisciplinary and multicenter collaboration and discussion to create new ideas and improve the approach for this complex radiation treatment procedure.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Local Ethics Committee of the Dmitriy Rogachev National Medical Research center of pediatric hematology, oncology and immunology. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s) and minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

DA collected and analyzed data and wrote the paper. AN, LS, and MM designed the study, analyzed data and reviewed the paper. FK, DT, and AL collected and analyzed data and wrote the paper. RK and MI collected and analyzed data and reviewed the paper. DB and NM contributed to study design and reviewed the paper. All authors contributed to the article and approved the submitted version.
REFERENCES

1. Davies SM, Ramsay NK, Klein JP, Weidorf DJ, Bolwell B, Cahn JY, et al. Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia. J Clin Oncol (2000) 18(2):340–7. doi: 10.1200/ jco.2010.18.2.340

2. Blume KG, Forman SJ, Snyder DS, Nademanee AP, O’Donnell MR, Fahey JL, et al. Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia During First Complete Remission. Transplantation (1987) 43(3):389–92. doi: 10.1097/00007890-198703000-00014

3. Glasgow GP, Wang S, Stanton J. A Total Body Irradiation Stand for Bone Marrow Transplant Patients. Int J Radiat Oncol Biol Phys (1989) 16(3):875–7. doi: 10.1016/0360-3016(89)90508-7

4. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oelfinger KC, et al. Twenty-Five-Year Follow-Up Among Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. Blood (2008) 111(12):5315–23. doi: 10.1182/blood-2007-11-17150

5. Ozsahin M, Pené F, Touboul E, LeFebvre L, Stein A, Rosenthal J, et al. Targeted Total Marrow Irradiation Using Three-Dimensional Image-Guided Tomographic Intensity-Modulated Radiation Therapy: An Alternative to Standard Total Body Irradiation. Biol Blood Marrow Transplant (2006) 12(3):306–15. doi: 10.1016/j.bbmt.2005.10.026

6. Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of Bone Marrow Transplant Patients. Radiother Oncol (2019) 124(1):12. doi: 10.1016/j.radonc.2019.03.033

7. Kelsey CR, Horwitz ME, Chino JP, Craciunescu O, Steffey B, Folz RJ, et al. Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: A Non-Randomized Comparative Study of Two Randomized Instantaneous Dose Rates in 157 Patients. Cancer (1992) 69(11):2853–65. doi: 10.1002/10.1992060119.90170

8. Blaise D, Maraninchi D, Michallet M, Reffiers J, Jouet JP, Milpied N, et al. Long-Term Follow-Up of a Randomized Trial Comparing the Combination of Cyclophosphamide With Total Body Irradiation or Busulfan as Conditioning Regimen for Patients Receiving HLA-Identical Marrow Grafts for Acute Myeloblastic Leukemia in First Complete Remission. Blood (2001) 97(11):3669–71. doi: 10.1182/blood.V97.11.3669

9. Kelsey CR, Horwitz ME, Chino JP, Ciaccione V, Steffey B, Folz RJ, et al. Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors. Int J Radiat Oncol Biol Phys (2011) 81(3):518–28. doi: 10.1016/j.ijrobp.2010.06.058

10. Kelsey CR, Horwitz ME, Chino JP, Ciaccione V, Steffey B, Folz RJ, et al. Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors. Int J Radiat Oncol Biol Phys (2011) 81(3):518–28. doi: 10.1016/j.ijrobp.2010.06.058

11. Abougidi E, Nanda RH, Butker C, Zhang C, Kim S, Chiang KY, et al. Safety of Total Body Irradiation Using Intensity-Modulated Radiation Therapy by Helical Tomotherapy in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Pilot Study. J Radiat Res (2020) 61(6):969–76. doi: 10.1093/jrr/rraa078

12. Shueng PW, Lin SC, Chong NS, Lee HY, Tien HJ, Wu LJ, et al. Total Marrow Irradiation With Helical Tomotherapy for Bone Marrow Transplantation of Multiple Myeloma: First Experience in Asia. Technol Cancer Res Treat (2009) 8(1):37. doi: 10.1177/1533034609008001003

13. Maschan M, Shchikhova L, Shchekhovtsova Z, Balashov D, Kurnikova E, Muzalevsky Y, et al. TCR-Alpha/Beta and CD19 Depletion in Haploidentical Transplantation From Matched Unrelated and Haploidentical Donors in Pediatric Leukemia Patients: Comparison of Two GVHD Prophylaxis Regimens. Biol Blood Marrow Transplant (2016) 22(3):385–5. doi: 10.1016/j.bbmt.2015.11.901

14. Maschan M, Shchikhova L, Ilshina M, Kurnikova E, Boyakova E, Balashov D, et al. TCR-Alpha/Beta and CD19 Depletion and Treosulfan-Based Conditioning Regimen in Unrelated and Haploidentical Transplantation in Children With Acute Myeloid Leukemia. Bone Marrow Transplant (2016) 51(5):668–74. doi: 10.1038/bmt.2015.343

15. Shchikhova L, Shchekhovtsova Z, Balashov D, Boyakova E, Muzalevsky Y, Gutovskaia E, et al. TCR-Alpha/Beta and CD19 Depletion in Haploidentical Transplantation From Matched Unrelated and Haploidentical Donors Following Treosulfan or TBI-Based Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients. Blood (2016) 128(22):4672. doi: 10.1182/blood.V128.22.4672-4672

16. Loginova AA, Kobyzeva DA, Tomvayan DA, Chernyavap AE, Lisovskyia AO, Maschan MA, et al. Comparison of Total Body Irradiation Using Tomotherapy and Volume-Modulated Rotational Radiation Therapy Elekta. A Single Center Experience on Pediatric Patients. Pediatr Hematol/Oncol Immunopath (2019) 18(4):49–57. doi: 10.24287/1726-1708-2019-18-4-49-57

17. Barrett A, Nicholls J, Gibson B. Late Effects of Total Body Irradiation. Radiother Oncol (1987) 9(2):131–5. doi: 10.1016/0167-8140(87)80200-1

18. Hui SK, Kapatos J, Fowler J, Henderson D, Oliveira G, Manon RR, et al. Feasibility Study of Helical Tomotherapy for Total Body or Total Marrow Irradiation. Med Phys (2005) 32(10):3214–24. doi: 10.1118/1.2044428

19. Schultheiss TE, Wong J, Liu A, Schultheiss T, Pleweell L, Stein A, Rosenthal J, et al. Targeted Total Marrow Irradiation Using Three-Dimensional Image-Guided Tomographic Intensity-Modulated Radiation Therapy: An Alternative to Standard Total Body Irradiation. Biol Blood Marrow Transplant (2006) 12(3):306–15. doi: 10.1016/j.bbmt.2005.10.026

20. Pengaraciano JA, Chao M, Van Rhee F, Moros EG, Corry PM, Ratanathanhorn V. Clinical Feasibility of TBI With Helical Tomotherapy. Bone Marrow Transplant (2011) 46:929–35. doi: 10.1038/bmt.2010.237

21. Schultheiss TE, Wong J, Liu A, Oliveira G, Somlo G. Image-Guided Total Marrow and Total Lymphatic Irradiation Using Helical Tomotherapy. Int J Radiat Oncol Biol Phys (2007) 67(4):1259–67. doi: 10.1016/j.ijrobp.2006.10.047

22. Wang JY, Liu A, Schultheiss T, Pleweell L, Stein A, Rosenthal J, et al. Targeted Total Marrow Irradiation Using Three-Dimensional Image-Guided Tomographic Intensity-Modulated Radiation Therapy: An Alternative to Standard Total Body Irradiation. Biol Blood Marrow Transplant (2006) 12(3):306–15. doi: 10.1016/j.bbmt.2005.10.026
33. Esiashvili N, Chiang KY, Hasselle MD, Bryant C, Riffenburgh RH, Paulino AC. Renal Toxicity in Children Undergoing Total Body Irradiation for Bone Marrow Transplantation. Radiat Oncol (2009) 90(2):242–6. doi: 10.1016/j.radonc.2008.09.017

34. Cheng JC, Schultheiss TE, Wong JY. Impact of Drug Therapy, Radiation Dose, and Dose Rate on Renal Toxicity Following Bone Marrow Transplantation. Int J Radiat Oncol Biol Phys (2008) 71(5):1436–43. doi: 10.1016/j.ijrobp.2007.12.009

35. Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR, et al. Toxicities of Total-Body Irradiation for Pediatric Bone Marrow Transplantation. Int J Radiat Oncol Biol Phys (1996) 34(4):843–51. doi: 10.1016/0360-3016(95)02178-7

36. Wheldon TE. The Radiobiological Basis of Total Body Irradiation. Brit J Radiol (1997) 70(840):1204–7. doi: 10.1259/bjr.70.840.9505837

37. Cox JD, Stetz J, Pajak TF. Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys (1995) 31(5):1341–46. doi: 10.1016/0360-3016(95)00060-C

38. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: Current Situation and Perspectives—A Position Statement From the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl (2015) 50(6):781–9. doi: 10.1038/bmt.2015.52

39. Mcdonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive Disease of the Liver After Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors. Hepatology (1984) 4(1):116–22. doi: 10.1002/hep.1840040121

40. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic Veno-Occlusive Disease Following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. Biol Blood Marrow Transplant (2010) 16(2):157–68. doi: 10.1016/j.bbmt.2009.08.024

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kobyzeva, Shelikhova, Loginova, Kanestri, Tovmasyan, Maschan, Khismatullina, Ilushina, Baidildina, Myakova and Nekesnivuk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.